Biotech company Illumina was fined $476 million by the European Union for acquiring cancer test company Grail without vetting from the EU, Bloomberg reported July 12.
Read the full post on Becker's Hospital Review - Healthcare News
EU hits Illumina with $476M fine for Grail acquisition
